Glycemic control in type 2 diabetes: from medication nonadherence to residual vascular risk
- PDF / 559,389 Bytes
- 5 Pages / 595.276 x 790.866 pts Page_size
- 39 Downloads / 243 Views
VIEWPOINT
Glycemic control in type 2 diabetes: from medication nonadherence to residual vascular risk Dario Giugliano
1
●
Maria Ida Maiorino2 Giuseppe Bellastella1 Katherine Esposito2 ●
●
1234567890();,:
Received: 21 December 2017 / Accepted: 29 December 2017 © Springer Science+Business Media, LLC, part of Springer Nature 2018
Abstract Despite the availability of many new treatment options for type 2 diabetes, the proportion of patients achieving the HbA1c target < 7.0% remains around 50%. We put forward the hypothesis that the unchanged HbA1c results, observed in the last decade in type 2 diabetes patients, are also a consequence of medication nonadherence and clinical inertia. Poor medicationtaking behavior is usually defined as medication nonadherence and is responsible for uncontrolled hemoglobin A1c level in 23% of cases. Medication nonadherence may also affect clinical outcomes, as diabetic patients with good adherence (≥80%) had a significant 10% lower rate of hospitalization events and a significant 28% lower rate of all-cause mortality when compared with patients with poor adherence (
Data Loading...
